Embryonic stem cells sustain a microenvironment that facilitates a balance of self-renewal and differentiation. Aggressive cancer cells, expressing a multipotent, embryonic cell-like phenotype, engage in a dynamic reciprocity with a microenvironment that promotes plasticity and tumorigenicity. However, the cancerassociated milieu lacks the appropriate regulatory mechanisms to maintain a normal cellular phenotype. Previous work from our laboratory reported that aggressive melanoma and breast carcinoma express the embryonic morphogen Nodal, which is essential for human embryonic stem cell (hESC) pluripotency. Based on the aberrant expression of this embryonic plasticity gene by tumor cells, this current study tested whether these cells could respond to regulatory cues controlling the Nodal signaling pathway, which might be sequestered within the microenvironment of hESCs, resulting in the suppression of the tumorigenic phenotype. Specifically, we discovered that metastatic tumor cells do not express the inhibitor to Nodal, Lefty, allowing them to overexpress this embryonic morphogen in an unregulated manner. However, exposure of the tumor cells to a hESC microenvironment (containing Lefty) leads to a dramatic down-regulation in their Nodal expression concomitant with a reduction in clonogenicity and tumorigenesis accompanied by an increase in apoptosis. Furthermore, this ability to suppress the tumorigenic phenotype is directly associated with the secretion of Lefty, exclusive to hESCs, because it is not detected in other stem cell types, normal cell types, or trophoblasts. The tumor-suppressive effects of the hESC microenvironment, by neutralizing the expression of Nodal in aggressive tumor cells, provide previously unexplored therapeutic modalities for cancer treatment.
The multipotent phenotype of metastatic cancer cells permits them to respond to cues normally restricted to developmental processes (1) . Hence, we hypothesized that embryonic microenvironments, which are inherently permissive to normal stem cell differentiation, may be used to reprogram (i.e., redifferentiate) cancer cells toward a benign phenotype. Indeed, embryonic microenvironments have been shown to inhibit the tumorigenicity of a variety of cancer cell lines (1, (9) (10) (11) . For example, the mouse embryonic microenvironment can reprogram teratocarcinoma cells to a nontumorigenic phenotype capable of differentiating into normal tissues (11) , and extracts derived from zebrafish embryos can inhibit proliferation and induce apoptosis in a number of cancer cell types. Moreover, we have demonstrated that exposure of metastatic melanoma cells to an embryonic zebrafish microenvironment, before gastrulation, results in their reprogramming toward a nontumorigenic phenotype (12, 13) and that metastatic melanoma cells transplanted into developing chick embryos are capable of following neural crest migration pathways, resulting in a loss of tumorigenicity and the acquisition of a neural crest-like phenotype (10) .
To elucidate the mechanisms by which embryonic microenvironments reprogram cancer cells to a more differentiated, less aggressive phenotype, so that humanized therapeutic modalities may be discovered, we developed an in vitro 3D model to investigate the capacity of hESC-derived factors to epigenetically influence metastatic cancer cells (1, 14) . Using this approach, we previously determined that exposure of melanoma cells to a hESC microenvironment results in the reexpression of melanocyte-specific markers (illustrative of redifferentiation) and a reduction in invasive potential (1, 14) . However, the molecular underpinnings of the reprogramming potential of the hESC microenvironment remained elusive. In the current study, we have discovered that hESC microenvironments suppress the tumorigenic phenotype of human metastatic melanoma and breast carcinoma cells and that this effect is exclusive to hESCs and not other stem cell types derived from amniotic fluid, cord blood, or adult bone marrow. Mechanistically, the hESC microenvironment specifically neutralizes the aberrant expression of Nodal in metastatic melanoma and breast carcinoma cells, reprogramming them to a less aggressive phenotype exemplified by diminished clonogenicity and tumorigenicity (with apoptosis). Moreover, we uncovered hESC-secreted Lefty (an inhibitor of Nodal signaling) as an important mediator of these phenomena. The microenvironment of hESCs provides a previously unexplored therapeutic entity for the regulation of aberrantly expressed embryonic factor(s) in aggressive tumor cells.
Results

Characterization of Nodal Signaling Pathway Members in Human
Normal Cells, Metastatic Cancer Cells, Human Embryonic Stem Cells (hESC), and Other Stem Cell Types. To better characterize the role of Nodal in the maintenance of pluripotency and tumorigenicity, we examined the expression of key components of the Nodal signaling pathway in human normal, neoplastic and stem cell types. Western blot analyses revealed that in a manner similar to hESCs (MEL-2, H1, and H9), metastatic melanoma (C8161) and breast carcinoma (MDA-MB-231) cells express Nodal protein at Ϸ48 kDa (Fig. 1A) . This is in contrast to corresponding normal cell types [melanocytes, myoepithelial cells (Hs 578 Bst), and primary human mammary epithelial cells (HMEpC)], in which Nodal was not detected. Using RT-PCR, we determined that Nodal is expressed in additional melanoma (WM278), and breast carcinoma (T47D, MDA-MB-468, MDA-MB-330, and ZR75-30) cell lines [supporting information (SI) Fig. 5A ]. Nodal propagates its signal by binding to a receptor complex comprised of Cripto and a heterodimer of type I (ALK 4/7) and type II (ActRIIB) activin-like kinase receptors. Genetic studies in zebrafish and mice have determined that Cripto directly associates with ALK 4 and Nodal and that these associations facilitate the ability of Nodal to propagate its signal (15, 16) . Using Western blot analysis and immunofluorescence microscopy, we determined that hESCs uniformly express high levels of Cripto at Ϸ35 kDa; however, only a low level of Cripto was heterogeneously expressed in C8161 and MDA-MB-231 cells ( Fig. 1 A and  B) . Moreover, only one additional melanoma line (WM278) and two additional breast carcinoma lines (T47D and ZR75-30) examined in this study expressed detectable levels of Cripto transcript (SI Fig. 5A ).
The Lefty proteins (Lefty-A and Lefty-B), divergent members of the TGF-␤ superfamily, spatially and temporally antagonize Nodal in embryological systems (17) . Moreover, the Lefty genes are downstream targets of Nodal signaling, thereby providing a powerful negative-feedback loop for this pathway (17) . By using Western blot analysis we determined that, in accordance with previously published accounts of Lefty protein processing patterns, hESCs express Lefty protein at Ϸ42, 34 and 28 kDa (17, 18) . In contrast, Lefty is not expressed by metastatic breast carcinoma and melanoma cells or by corresponding normal somatic cell types ( Fig. 1 A  and SI Fig. 5A ). To visualize the localization of Lefty and Nodal in hESC colonies and their microenvironment, we performed immunofluorescence localization with confocal microscopy. Using this method, we determined that Lefty protein localizes to the areas where hESCs contact the underlying Matrigel matrix, and that hESC-derived Lefty permeates into this microenvironment (Fig.  1C) . This is in contrast to Nodal protein, which localizes to the surface of hESC colonies, and is secreted into the media. These results were confirmed with Western blot analyses, which demonstrated that Lefty protein can be detected in Matrigel conditioned by H9 hESCs (H9 CMTX; Fig. 1C ). Furthermore, neither Nodal nor Lefty is found in unconditioned control Matrigel alone (data not shown).
We next sought to elucidate the expression of Nodal, Lefty, and Cripto in other human stem cell types and in first trimester human cytotrophoblast cells (HTR-8/SVneo). Western blot analyses revealed that umbilical-cord-derived mesenchymal stem cells (MSC; SC00125) and adult MSCs do not express Nodal and Cripto, and that although amniotic-fluid-derived stem cells (GM00473, GM00957A) and cytotrophoblast cells express Cripto, only the latter expresses appreciable levels of Nodal (SI Fig. 5B ). Of note, in contrast to hESCs, none of the other stem cell lines examined expressed an appreciable level of Lefty protein (SI Fig. 5B ). To , and type II (ActRIIB) activin-like kinase receptors and is regulated via a positive feedback loop. hESCs also secrete Nodal inhibitors, including Lefty, which is up-regulated in response to Nodal but antagonizes the Nodal signaling pathway by interacting with Nodal and/or Cripto. Like hESCs, cancer cells also express Nodal, whereas unlike hESCs they do not express Lefty. HESC-derived Lefty, found in hESC conditioned matrices (CMTX), may inhibit Nodal signaling in cancer cells and promote their reprogramming toward a less malignant phenotype. Other tumor suppressive factors also may be deposited by the hESCs.
confirm the apparent exclusivity of Lefty expression to hESCs, we performed real-time RT-PCR. Using this method, we determined that relative to hESCs, metastatic cancer cells, normal somatic cells and trophoblast cells do not express appreciable levels of Lefty mRNA (SI Fig. 5C ). Moreover, the other stem cell types used in this study expressed a comparably insignificant level of Lefty (SI Fig.  5C ). We previously demonstrated that Nodal expression is positively correlated with melanoma progression, such that Nodal protein is not expressed in normal melanocytes or radial growth phase melanomas, but is present in vertical growth phase and metastatic lesions (4). The current study characterized Nodal localization (previously unexplored) in breast tissues: Using immunohistochemical analysis of a human breast tissue microarray (TMA) we observed that Nodal protein is absent in normal breast tissue, and that its expression is positively correlated with breast cancer progression (P Ͻ 0.05; SI Fig. 5D and SI Table 1 ). Given the significant observation that like hESCs, cancer cells express Nodal, although unlike hESCs, they do not express Lefty, we hypothesized that hESC-derived Lefty and possibly other tumor-suppressive factors found in hESC-conditioned matrices (CMTX), may inhibit Nodal signaling in cancer cells (Fig. 1D) . We further proposed that by neutralizing Nodal in cancer cells, hESC microenvironments will reprogram these tumor cell types toward a less tumorigenic phenotype.
Exposure of Cancer Cells to hESC-Derived Factors, Particularly Lefty, Results in Decreased Nodal Expression Concomitant with Reduced
Clonogenicity. To examine the effect of hESC-derived Lefty on tumor cell phenotype, we used Dynabeads covalently coupled to anti-Lefty antibody to isolate Lefty from hESCs cultured on a feeder-free Matrigel matrix. The specificity and utility of the anti-Lefty antibody used to recover Lefty protein was confirmed by Western blot analysis and corresponding Coomassie stained SDS/ PAGE of known rLefty-A and -B standards whose sequences were subsequently confirmed by liquid chromatography/mass spectrometry (LC/MS; SI Fig. 6A ). Purified hESC-derived Lefty was seeded into Matrigel and the effects of the ''Lefty-containing'' matrix on cancer cell phenotype were determined. Western blot analysis revealed that hESC-derived Lefty significantly diminished Nodal protein expression in C8161 and MDA-MB-231 cells ( Fig. 2A) .
To further substantiate the specificity of these results, the cancer cells were also exposed to Matrigel conditioned by hESCs in which Lefty protein expression was knocked down with FITC-tagged Morpholinos specific for Lefty-A and Lefty-B (MO LEFTY ). [The fluorescently tagged Morpholinos could be detected microscopically in Ͼ75% of the hESC colonies treated (SI Fig. 6B Upper) , and Western blot analysis confirmed the efficient knock down of Lefty protein in hESCs for up to 3 days (SI Fig. 6B Lower) ]. The expression of Oct-3/4 and Nanog, representative of pluripotency, was not affected during this time, and morphology of the hESC colonies was not altered (SI Fig. 6C ). Thus, although MO LEFTY knocked down Lefty protein in the hESCs, it did not induce stem cell differentiation during this window of observation. Western blot analysis revealed that C8161 and MDA-MB-231 cells up-regulate Nodal protein expression in response to this ''H9 Lefty-deficient'' hESC matrix (Fig. 2B ). C8161 and MDA-MB-231 cells treated with rNodal (100 ng/ml) similarly experienced an up-regulation of Nodal mRNA expression (SI Fig. 6D ), and hESCs treated with MO LEFTY up-regulated Nodal protein expression (Fig. 2B) . These findings are in accordance with the positive feed-back loop that characterizes the Nodal signaling pathway. In contrast to rNodal, which has biological activity, previous studies have reported that recombinant Lefty protein (rLefty) is unable to inhibit Nodal signaling (17) . We confirmed these results and extended them to discover that rLefty-B can inhibit Nodal protein in C8161 cells, but at a nonphysiological dose (1,000 ng/ml) (SI Fig. 6E ). In an effort to understand the disparate results between hESC-derived Lefty and rLefty on Nodal signaling, we analyzed glycoprotein content in rLefty-B, rLefty-A and a lysate from the H9 hESCs plus their CMTX. We determined that in an apparent contrast to the rLefty proteins, H9-derived Lefty is glycosylated (SI Fig. 6F) .
As a functional correlate, we determined that exposure of C8161 and MDA-MB-231 cells to H9 Lefty-derived matrix significantly reduces anchorage-independent growth, and that this inhibition of in vitro clonogenicity can be rescued by the inclusion of recombinant Nodal (rNodal; 100 ng/ml) (Fig. 2C) . Furthermore, exposure of C8161 and MDA-MB-231 cells to H9 CMTX reduced their ability to undergo anchorage-independent growth but this inhibition of in vitro clonogenicity was only partially rescued by the inclusion of rNodal (100 ng/ml) (Fig. 2D) . In addition, hESC supernatant inhibited anchorage-independent growth, even when Lefty was decreased via the aforementioned Dynabead isolation, although not to the same level as purified Lefty. Collectively, these findings suggest that hESC-derived Lefty has important anti-tumorigenic potential, but that it is not the only tumor suppressive factor within this unique embryonic microenvironment.
We next determined the effects of H9 CMTX on Nodal expression in C8161 and MDA-MB-231 cells. Real-time RT-PCR showed that exposure to H9 CMTX down-regulates Nodal mRNA expression in both C8161 and MDA-MB-231 cells, and that this effect is reversible over time (Fig. 3A) . Exposure to H9 CMTX similarly decreases Nodal protein expression in these cells (SI Fig. 7A ). Exposure of C8161 cells to matrices conditioned by adult bonemarrow-derived stem cells (MSC), amniotic-fluid-derived stem cells (GM00473, GM00957A), or cytotrophoblast cells (HTR-8/ SVneo) did not inhibit Nodal mRNA or protein expression ( Fig. 3B  and SI Fig. 7B ), thus illuminating the exclusivity of the epigenetic influence of the hESC microenvironment.
The Microenvironment of hESCs Inhibits Melanoma and Breast Carcinoma Tumorigenicity. We implemented orthotopic mouse models to examine the effects of the hESC microenvironment on the in vivo tumorigenicity of melanoma and breast carcinoma cells. Exposure of C8161 and MDA-MB-231 cells to H9 CMTX resulted in a significant reduction in tumorigenicity compared with cells exposed to unconditioned Matrigel (Fig. 4 A and B) . To establish a mechanism for the reduction in tumorigenicity, we examined the effects of this treatment on in vivo tumor cell proliferation and apoptosis. Using immunohistochemical staining for Ki67 as a measure of proliferation, and terminal deoxynucleotidyl transferase biotindUTP nick-end labeling (TUNEL) as a measure of apoptosis, we found that exposure to hESC CMTX decreased proliferation and increased apoptosis in C8161 and MDA-MB-231 cells (Fig. 4C and  SI Fig. 8 ). These in vivo data confirm the tumor suppressive effects of the hESC microenvironment on aggressive melanoma and breast cancer cells and implicate the potential involvement of apoptotic pathways.
Discussion
Studies dating back to the 1970s and continuing to present day have documented the ability of embryonic microenvironments to reprogram cancer cells toward a benign phenotype (1, 19) ; however, the mechanisms underlying this phenomenon have remained largely illusive. This study applied an in vitro hESC model to specifically demonstrate the anti-tumorigenic properties of the human embryonic microenvironment, and the possible underlying mechanisms. Of significance, our results indicate that: (i) The tumor suppressive effects of the microenvironment are exclusive to hESCs, but not other stem cell types; (ii) the hESC microenvironment neutralizes the expression of the embryonic morphogen Nodal in metastatic melanoma and breast carcinoma cells, reprogramming them to a less aggressive phenotype exemplified by diminished clonogenicity and tumorigenicity (with increased apoptosis); and (iii) Lefty, an inhibitor of the Nodal signaling pathway, is secreted into the hESC microenvironment and is an important mediator of these tumorsuppressive effects. These findings illuminate an embryological signaling pathway that is aberrantly reexpressed in metastatic melanoma (neural crest derived) and breast carcinoma cells (epithelial origin) that could be targeted for the reprogramming of aggressive tumor cells with unique embryonic regulator(s).
Nodal is required to preserve the pluripotency of hESCs and our recent work revealed that Nodal signaling maintains the dedifferentiated multipotent phenotype of highly metastatic C8161 melanoma cells (4, 20, 21) . The present study showed that this protein is restricted to aggressive cancer cells, embryonic stem cells, and trophoblasts, and that it is not associated with normal differentiated cell types or with more specified MSCs. Hence, Nodal expression was restricted to embryonic and cancer cell types. Of note, the Nodal gene has been sequenced in the hESCs and melanoma cells used in this study, and no differences or point mutations have been detected (M. Bento Soares, personal communication). This study further demonstrated that Cripto, a prominent mediator of the Nodal signaling pathway in embryological systems, also is restricted to multipotent cancer and stem cell fates. Previous studies, from other laboratories, determined that like Nodal, Cripto is expressed in cancer, specifically testicular, colon and breast cancer cells, but is rarely detected in normal adult tissues (22) (23) (24) . Furthermore, Cripto is a stem cell marker for pluripotent hESCs and has been associated with dedifferentiation, vascularization and invasion in breast carcinoma cells (23, 25, 26) . These functions mirror those of Nodal in melanoma, inferring a convergence of their tumorpromoting functions. Relative to hESCs, Cripto was very weakly and heterogeneously expressed in the metastatic melanoma and breast carcinoma cells used in this study. This finding is intriguing, and raises the possibility that the Cripto-positive cells represent a unique side population. However, because of the disproportionately low levels of Cripto observed in these cancer cells, we suggest that it is unlikely that modulations in Cripto contributed significantly to the results obtained in our study. Furthermore, we speculate that Nodal may be propagating its signal by binding to and activating the ALK 4/7 receptor complex via a Cripto-independent mechanism (please refer to Fig. 1D) .
In embryological systems Nodal is regulated via a positive feedback loop (1, 15) . To control this system, and enable alternative cell fate decisions, endogenous inhibitors such as Lefty-A, Lefty-B, and Cerberus, are used (1, 15) . In conjunction with Nodal and Oct 3/4, Lefty-A and -B are among the most enriched genes expressed in hESCs, exemplifying the putative importance of these inhibitors (17, 27) . We determined that neither the cancer cells nor the normal somatic cells used in this study express Lefty. In fact Lefty expression was unique to hESCs: Other human stem cell types (including those derived from amniotic fluid, umbilical cord blood, and adult bone marrow) and embryo-associated human cytotrophoblast cells did not express appreciable levels of this protein. Furthermore, unlike H9 CMTX, matrices conditioned by these more committed stem cell lineages were unable to inhibit Nodal expression in aggressive melanoma cells. These results highlight the inherent differences between hESCs and other stem cell types, and suggest that certain therapeutic modalities may be derived exclusively from hESCs.
The results of our study demonstrate that exposure to a hESC microenvironment down-regulates Nodal signaling in melanoma and breast cancer cells, associated with a reduction in clonogenicity and tumorigenicity. However, this suppressive effect is transient and reversible. To decipher the molecular underpinnings of the suppressive effects of the hESC microenvironment on tumor cells, we focused on the deposition of Lefty (Nodal's inhibitor sequestered in the embryonic milieu) and asked whether the cancer cells that do not express Lefty could in fact respond to Lefty produced by hESCs. In a manner similar to H9 CMTX, exposure to H9-derived Lefty down-regulated Nodal expression in melanoma and breast carcinoma cells, and decreased clonogenicity in both tumor cell types as well. We were able to rescue the effect of H9-derived Lefty on clonogenicity with rNodal, suggesting that the results obtained with this treatment were due specifically to a reduction in Nodal. Further confirmation of these findings showed H9 hESCs treated with MO LEFTY were unable to inhibit Nodal expression in the C8161 and MDA-MB-231 cells. In fact, exposure of these tumor cells to matrix conditioned by the Lefty-deficient hESCs resulted in a significant up-regulation of Nodal expression, which we postulate is because of a feed-forward response of Nodal-expressing tumor cells to the overproduction of Nodal by the hESCs. Finally, exposure to H9 CMTX reduced anchorageindependent growth, but in contrast to purified hESC-derived Lefty, this effect could not be completely rescued by the inclusion of rNodal. Collectively, these results suggest that Lefty plays an important role in the ability of the hESC microenvironment to suppress the tumorigenic phenotype, but that it is not the only inhibitory component.
Previous work from another laboratory reported that addition of Lefty protein to hESC cultures, even at a high, nonphysiological dose of 200 ng/ml, failed to inhibit Nodal and induce hESC differentiation (17) . Our results showed that although Nodal could be inhibited in C8161 melanoma cells, it required Ն1,000 ng/ml of recombinant Lefty (rLefty) to reach a measurable level of response by the cells. By comparison, Lefty recovered from hESCs (plus their CMTX) inhibited Nodal in C8161 and MDA-MB-231 cells at a significantly lower concentration (estimated in the range of 20-50 ng/ml). These observations led us to examine whether rLefty is significantly different from hESC-derived Lefty in terms of glycosylation because glycosylation is typical for proteins made by eukaryote cells, but not characteristic of proteins made recombinantly (e.g., through bacterial transduction). We found that commercially available rLefty A and rLefty B are not glycosylated by using the Pro-Q Emerald 300 staining kit, whereas Lefty recovered from hESCs (plus CMTX) is glyosylated, which could ultimately affect how this protein functions physiologically, and may provide a possible explanation for these disparate observations.
Although exposure to a hESC microenvironment inhibits Nodal expression and tumorigenicity in both melanoma and breast carcinoma cells, the breast cancer cells undergo a more complex reprogramming event. Although melanoma cells respond to the hESC-derived factors within 3 days, the breast carcinoma cells require 2 additional days to achieve the most significant downregulation in Nodal. This discrepancy is likely attributable to differences in signaling mechanisms between these two cell types. For example, although C8161 cells do not express TGF-␤1, which like Nodal uses Smad-2 as a signaling mediator, MDA-MB-231 cells actively employ this system, enabling the continued phosphorylation of Smad-2, which may sustain Nodal expression for a longer duration (4, 28) . Despite the inherent differences between neural crest-derived melanoma cells and epithelial-derived breast carcinoma cells, these divergent tumor types both underwent apoptosis after exposure to hESC CMTX. This remarkable similarity is likely attributable to the commonality of plasticity (e.g., the aberrant and unregulated expression of Nodal) that indiscriminately unifies highly aggressive cancer cells, regardless of their origin.
This study used an innovative approach to address whether aggressive cancer cells, expressing a plastic, embryonic-like phenotype, could respond to regulatory cues that control cell fate determination within the microenvironment of hESCs and other stem cell types. We revealed that aggressive cancer cells, but not normal cell types, express the embryonic morphogen Nodal, which is essential to the maintenance of hESC pluripotency, but unlike hESCs, the tumor cells lack Lefty, a negative regulator of Nodal. Down-regulation of Nodal expression via exposure to the hESC microenvironment (containing Lefty) resulted in a reduction in clonogenicity and tumorigenesis accompanied by an increase in apoptosis. Particularly noteworthy is the finding associated with the exclusivity of the hESC microenvironment to down-regulate Nodal expression in aggressive tumor cells, because it is not observed with other stem cell types (isolated form amniotic fluid, cord blood, or adult bone marrow) or trophoblasts, which do not express Lefty. Understanding the tumor-suppressive effect(s) of the hESC microenvironment, together with the importance of its influence on the Nodal signaling pathway, may offer new therapeutic strategies to inhibit tumor progression.
Materials and Methods
Cell Culture. Human cutaneous melanoma (C8161, WM-278) and breast carcinoma (MDA-MB-231, MCF-7, T47D, MDA-MB-468, MDA-MB-330 and ZR75-30) lines were maintained as described (29 -31) were maintained under the recommended conditions. HTR-8/SVneo is a well characterized human extravillous cytotrophoblast cell line, and was maintained as described in ref. 32 . H1 and H9 hESCs (WiCell, Madison WI) and MEL-2 hESCs (Millipore) were maintained as described in ref. 14. For conditioned matrix experiments, hESCs were maintained in stem cell medium preconditioned on irradiated mouse embryonic fibroblasts (CF-1, ATCC) as described in ref. 14. Recombinant Nodal and Lefty (R&D Systems) were diluted as per manufacturer suggestions.
3D Conditioned Matrix Experiments. Conditioned matrices were prepared by using hESCs, melanocytes, myoepithelial cells, amniotic-fluid-derived stem cells, or trophoblast cells on growth factor-reduced Matrigel (14 mg/ml; BD Biosciences) as described in ref. 14. Alternatively, hESC-derived Lefty protein was seeded into Matrigel before polymerization (for complete methods outlining the
